TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus ...

TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an ...

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that it has entered into a license and supply agreement with Medinova AG, a Swiss pharmaceutical company, ...

Dec 15 (Reuters) - Acerus Pharmaceuticals Corporation : * Acerus pharmaceuticals corporation- acerus is eligible to receive a milestone payment upon regulatory approval of natesto in south korea Sign ...

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with ...

TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that it will be offering rights (the "Rights Offering") to ...

Re-purchased all remaining NATESTO® rights from Aytu Biopharma, allowing Acerus to build and leverage its commercial business across North America Expanded NATESTO® access to 20 countries across ...

The table below includes insider transactions amounts, trade dates and executives completing transactions. ACERUS PHARMACTICALS CP by Acerus Pharmaceuticals Corp. insider trades include the CEO, CFO, ...

TORONTO — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation of ...

Within 90 days of the effectiveness of the acquisition (the “Acquisition”), Acerus will pay a $6 million USD up-front fee to Serenity, less certain deductions allowed by the Definitive Agreement.

* ACERUS PHARMACEUTICALS - ‍CREDIT FACILITY BEARS INTEREST AT A RATE EQUIVALENT TO BANK OF CANADA PRIME PLUS 11.05% AND MATURES ON DECEMBER 1, 2019 * ACERUS PHARMACEUTICALS CORPORATION - ENTERED INTO ...